MA33924B1 - Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a - Google Patents

Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a

Info

Publication number
MA33924B1
MA33924B1 MA35065A MA35065A MA33924B1 MA 33924 B1 MA33924 B1 MA 33924B1 MA 35065 A MA35065 A MA 35065A MA 35065 A MA35065 A MA 35065A MA 33924 B1 MA33924 B1 MA 33924B1
Authority
MA
Morocco
Prior art keywords
patient
relates
inhibitors
formula
administration
Prior art date
Application number
MA35065A
Other languages
Arabic (ar)
English (en)
Inventor
Ask Püschl
Jacob Nielsen
Jan Kehler
John Paul Kilburn
Mauro Marigo
Morten Langgård
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA33924B1 publication Critical patent/MA33924B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention a pour objet des composés qui sont des inhibiteurs de l'enzyme PDE10A. La présente invention concerne une composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un composé selon l'invention et un véhicule pharmaceutiquement acceptable. La présente invention concerne également des procédés pour la préparation des composés de formule (I). La présente invention concerne en outre une méthode de traitement d'un sujet souffrant d'un trouble neurodégénératif comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I). La présente invention concerne également une méthode de traitement d'un sujet souffrant d'une pharmacodépendance comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I). La présente invention concerne en outre une méthode de traitement d'un sujet souffrant d'un trouble psychiatrique comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I).
MA35065A 2009-12-17 2010-12-15 Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a MA33924B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28732409P 2009-12-17 2009-12-17
DKPA200901341 2009-12-17
PCT/DK2010/050343 WO2011072696A1 (fr) 2009-12-17 2010-12-15 Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a

Publications (1)

Publication Number Publication Date
MA33924B1 true MA33924B1 (fr) 2013-01-02

Family

ID=44246810

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35065A MA33924B1 (fr) 2009-12-17 2010-12-15 Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a

Country Status (34)

Country Link
US (2) US8501797B2 (fr)
EP (1) EP2513105B1 (fr)
JP (1) JP5698761B2 (fr)
KR (1) KR101777889B1 (fr)
CN (1) CN102753551B (fr)
AR (1) AR079498A1 (fr)
AU (1) AU2010333437B2 (fr)
CA (1) CA2783727C (fr)
CO (1) CO6612246A2 (fr)
CR (1) CR20120317A (fr)
CY (1) CY1115278T1 (fr)
DK (1) DK2513105T3 (fr)
DO (1) DOP2012000168A (fr)
EA (1) EA021415B1 (fr)
ES (1) ES2484692T3 (fr)
GE (1) GEP20156242B (fr)
GT (1) GT201200180A (fr)
HK (1) HK1177739A1 (fr)
HR (1) HRP20140632T1 (fr)
MA (1) MA33924B1 (fr)
MX (1) MX2012007144A (fr)
MY (1) MY158202A (fr)
NZ (1) NZ600416A (fr)
PL (1) PL2513105T3 (fr)
PT (1) PT2513105E (fr)
RS (1) RS53413B (fr)
SG (1) SG181536A1 (fr)
SI (1) SI2513105T1 (fr)
SM (1) SMT201400114B (fr)
TN (1) TN2012000287A1 (fr)
TW (1) TWI481607B (fr)
UA (1) UA107817C2 (fr)
WO (1) WO2011072696A1 (fr)
ZA (1) ZA201204418B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI481607B (zh) * 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
KR102325775B1 (ko) 2010-12-17 2021-11-12 노파르티스 아게 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
US8513436B2 (en) 2010-12-17 2013-08-20 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
EP3210984B1 (fr) 2011-01-11 2019-06-19 Sunovion Pharmaceuticals Inc. Composés hétéroaryles et procédés d'utilisation correspondants
CN103476757A (zh) 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
HUE028451T2 (en) * 2011-08-25 2016-12-28 Merck Sharp & Dohme Pyrimidine PDE10 inhibitors
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013107856A1 (fr) * 2012-01-20 2013-07-25 H. Lundbeck A/S Dérivés d'imidazole utilisés comme inhibiteurs d'enzymes pde10a
WO2013127817A1 (fr) 2012-02-27 2013-09-06 H. Lundbeck A/S Dérivés d'imidazole comme inhibiteurs de l'enzyme pde10a
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
SG11201903892UA (en) * 2016-11-02 2019-05-30 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
AR040847A1 (es) * 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos
AU2003288352A1 (en) 2002-10-30 2004-06-07 Centre National De La Recherche Scientifique (Cnrs) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
ATE438398T1 (de) 2003-06-30 2009-08-15 Nycomed Gmbh Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
CA2530316A1 (fr) 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines comme inhibiteurs de pde10
EP1651251A4 (fr) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
WO2005014588A1 (fr) 2003-08-01 2005-02-17 Argenta Discovery Limited Acides hydroxamiques de thienyle substitues presentant une activite de deacetylase
EP1723134A2 (fr) 2004-02-18 2006-11-22 Pfizer Products Incorporated Derives tetrahydroisoquinolinyliques de quinazoline et d'isoquinoline
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US20090162286A1 (en) 2004-06-07 2009-06-25 Pfizer Inc. Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
EP1802585A1 (fr) 2004-09-03 2007-07-04 Memory Pharmaceuticals Corporation Derives de 4, 6-dialkoxy-cinnoline substitues en position 4 en tant qu'inhibiteurs de phospodiesterase 10 pour le traitement de syndromes psychiatriques ou neurologiques
US20090176829A1 (en) * 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
JP2009542732A (ja) * 2006-07-10 2009-12-03 ハー・ルンドベック・アクチエゼルスカベット ６，７−ジアルコキシキナゾリン、６，７−ジアルコキシフタラジンおよび６，７−ジアルコキシイソキノリンの（３−アリール−ピペラジン−１−イル）、（２−アリール−モルホリン−４−イル）および（２−アリール−チオモルホリン−４−イル）誘導体
WO2009011880A2 (fr) 2007-07-17 2009-01-22 Amgen Inc. Modulateurs hétérocycliques de pkb
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物

Also Published As

Publication number Publication date
WO2011072696A1 (fr) 2011-06-23
HK1177739A1 (en) 2013-08-30
US20120302548A1 (en) 2012-11-29
EA021415B1 (ru) 2015-06-30
SI2513105T1 (sl) 2014-11-28
KR20120123276A (ko) 2012-11-08
DOP2012000168A (es) 2012-11-30
JP5698761B2 (ja) 2015-04-08
CA2783727A1 (fr) 2011-06-23
ES2484692T3 (es) 2014-08-12
AU2010333437B2 (en) 2016-09-01
TWI481607B (zh) 2015-04-21
MY158202A (en) 2016-09-15
CA2783727C (fr) 2018-02-20
RS53413B (en) 2014-12-31
CN102753551A (zh) 2012-10-24
HRP20140632T1 (hr) 2014-09-26
TN2012000287A1 (en) 2013-12-12
KR101777889B1 (ko) 2017-09-12
MX2012007144A (es) 2012-07-03
US20130289038A1 (en) 2013-10-31
SMT201400114B (it) 2014-11-10
SG181536A1 (en) 2012-07-30
JP2013514285A (ja) 2013-04-25
AR079498A1 (es) 2012-02-01
CY1115278T1 (el) 2017-01-04
NZ600416A (en) 2013-08-30
PL2513105T3 (pl) 2014-09-30
EP2513105B1 (fr) 2014-05-14
US8927738B2 (en) 2015-01-06
EP2513105A1 (fr) 2012-10-24
ZA201204418B (en) 2013-08-28
UA107817C2 (en) 2015-02-25
EA201290518A1 (ru) 2013-01-30
DK2513105T3 (da) 2014-07-14
CR20120317A (es) 2012-08-16
GT201200180A (es) 2015-01-16
CO6612246A2 (es) 2013-02-01
TW201127831A (en) 2011-08-16
US8501797B2 (en) 2013-08-06
CN102753551B (zh) 2014-10-22
PT2513105E (pt) 2014-07-31
AU2010333437A1 (en) 2012-06-21
GEP20156242B (en) 2015-02-10

Similar Documents

Publication Publication Date Title
MA33924B1 (fr) Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
MA33922B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
MY152949A (en) Novel phenylimidazole derivatives as pde10a enzyme inhibitors
IN2015DN02829A (fr)
UA112065C2 (uk) Похідні імідазолу як інгібітори ферменту pde10a
PH12014501695B1 (en) Pde9 inhibitors with imidazo triazinone backbone
UA102693C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
EA201290517A1 (ru) Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a
MX2013012588A (es) Inhibidores de cinasa.
MX2010009462A (es) Derivados de indazol.
BRPI0917245B8 (pt) compostos derivados de isoquinolinona e sua composição farmacêutica
MX336915B (es) Derivados de imidazol como inhibidores de la enzima pde10a.
TN2013000200A1 (en) Imidazole derivatives as pde 10a enzyme inhibitors
CY1116689T1 (el) Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a
MX2019014982A (es) Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos.
TN2014000288A1 (en) Pde9 inhibitors with imidazo triazinone backbone